Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Bioheart group to advance BRIDGE TO RECOVERY clinical trial

Bioheart, Inc. announced today that at the American Heart Association Annual Meeting, it finalized the formation of a working group. The group's focus is to advance a BRIDGE TO RECOVERY clinical trial, combining a left ventricle assist device (LVAD) and Bioheart's MyoCell adult muscle stem cell composition and Bioheart's MyoCath needle tipped catheter delivery system.

9 Dec 2010

Poorly educated people more likely to be admitted in hospital with chronic heart failure

Results from a large European study suggest that poorly educated people are more likely to be admitted to hospital with chronic heart failure than the better educated, even after differences in lifestyle have been taken into account. The study is published online today (Thursday 9 December) in the European Heart Journal.

9 Dec 2010

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous administration of VELCADE (bortezomib) in patients with relapsed multiple myeloma. These data were presented at the 52nd annual meeting of the American Society of Hematology, held December 4-7 in Orlando, Florida.

8 Dec 2010

Detection of blood biomarker cTnT associated with structural heart disease

With the use of a highly sensitive test, detection of the blood biomarker cardiac troponin T, a cardiac-specific protein, is associated with structural heart disease and an increased risk of all-cause death, according to a study in the December 8 issue of JAMA.

8 Dec 2010

Overeating and drinking at holiday parties could affect those unaware of type 2 diabetes

For most people, overeating and drinking at holiday parties will just result in weight gain. However, for millions of others who do not know they have type 2 diabetes, it could mean something much more serious.

8 Dec 2010

Study examines impact of poor care coordination on quality, cost of care in America

Many Americans seek medical treatment from a variety of care providers and often must play the role of informing each doctor what the others are recommending or prescribing. This fragmented experience of poorly coordinated care is due in part to a lack of consistent systems and processes in place to coordinate care across providers and facilities.

8 Dec 2010

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

Cephalon, Inc. and Mesoblast Limited, today announced they have entered into a strategic alliance to develop and commercialize novel adult Mesenchymal Precursor Stem Cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems.

8 Dec 2010

Company reaches $28 million settlement for Medicare program

The Tennesseean: "Healthways Inc. will return $28 million to Medicare's overseer under a settlement related to the company's participation in a pilot program to determine the effectiveness of its nurse-based health coaching for chronically ill seniors." The Centers for Medicare and Medicaid Services had paid the company $72 million for the pilot program, which ended two years ago, under the condition that it meet "specific targets for cost savings, health outcomes and patient satisfaction."

7 Dec 2010

New sensitive blood test could determine unrecognized heart disease

A more sensitive version of a blood test typically used to confirm that someone is having a heart attack could indicate whether a seemingly healthy, middle-aged person has unrecognized heart disease and an increased risk of dying, UT Southwestern Medical Center researchers have found.

7 Dec 2010

MU researcher hopes to protect cardiac muscles for children with DMD

Children with Duchenne muscular dystrophy face a future of rapidly weakening muscles, which usually leads to death by respiratory or cardiac failure before their 30th birthday. While researchers are hopeful that gene therapy could eventually evolve into an effective treatment, few have targeted the heart of the problem as much as Dongsheng Duan, PhD.

7 Dec 2010

Loyola nurses honored

Loyola University Health System revenue specialist Judy Williams, RN, CEN, TNS, recently took on a nontraditional nursing role, which resulted in a significant cost savings for the organization. Williams oversees fiscal responsibility for the Emergency Department. In this position, she has identified opportunities to overcome billing obstacles through intradepartmental collaboration and nurse education on proper documentation for reimbursement.

3 Dec 2010

CRT therapy is cost-effective for symptomatic heart failure patients: REVERSE trial

Medtronic, Inc. announced findings from an economic sub-study of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial published in the European Heart Journal demonstrating for the first time that cardiac resynchronization therapy (CRT) is cost-effective in mildly symptomatic heart failure (HF) patients.

3 Dec 2010

AHA: Incidence of hospitalization for heart valve diseases rises in New York

The incidence of hospitalization and treatment for heart valve diseases in New York State has constantly and progressively risen since the early 1980s, according to research presented at the recent meeting of the American Heart Association (AHA) by SUNY Downstate Medical Center. The study results were published in a supplement to the AHA journal, Circulation.

3 Dec 2010

Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast cancer

Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), in combination with paclitaxel (with or without bevacizumab) in patients with locally recurrent or metastatic breast cancer.

3 Dec 2010

FDA approves Abiomed to begin MINI-AMI trial to evaluate Impella 2.5

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) to begin MINI-AMI, a prospective, randomized, controlled multi-site trial to assess the potential role of the Impella 2.5 in reducing infarct size in patients with ST-elevation myocardial infarction (STEMI).

2 Dec 2010

Physician-led models of care benefit patients, health system

To best meet the goals of optimized, coordinated patient care and also help curb health care costs, physicians should be the heart of accountable care organizations (ACOs), an evolving model of patient care. The American Medical Association today outlined recommendations to make this a reality in comments provided to the Center for Medicare and Medicaid Services (CMS).

2 Dec 2010

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Pfizer Inc. announced today that the European Commission has approved SUTENT (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults.

2 Dec 2010

Loyola's mortality rate from heart-bypass surgery 74% lower than at peer hospitals

Loyola University Hospital's mortality rate from heart-bypass surgery is 74 percent lower than the mortality rate at peer hospitals, according to Thomson Reuters Cardiovascular Benchmarks Report.

1 Dec 2010

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of golimumab 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.

30 Nov 2010

Heart Failure News and Research

Further Reading

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Bioheart group to advance BRIDGE TO RECOVERY clinical trial

Poorly educated people more likely to be admitted in hospital with chronic heart failure

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Detection of blood biomarker cTnT associated with structural heart disease

Overeating and drinking at holiday parties could affect those unaware of type 2 diabetes

Study examines impact of poor care coordination on quality, cost of care in America

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

Company reaches $28 million settlement for Medicare program

New sensitive blood test could determine unrecognized heart disease

MU researcher hopes to protect cardiac muscles for children with DMD

Loyola nurses honored

CRT therapy is cost-effective for symptomatic heart failure patients: REVERSE trial

AHA: Incidence of hospitalization for heart valve diseases rises in New York

Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast cancer

FDA approves Abiomed to begin MINI-AMI trial to evaluate Impella 2.5

Physician-led models of care benefit patients, health system

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Loyola's mortality rate from heart-bypass surgery 74% lower than at peer hospitals

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News